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In this article, we compared the early and long-term outcomes of patients with metastatic co-
lorectal cancer treated with chemotherapy followed by resection with those of patients un-
dergoing surgery first, focusing our analysis on resection margin status. Patients who underwent
liver resection with curative intent for colorectal liver metastases from July 2001 to January 2018
were included in the analysis. Propensity score matching was used to reduce treatment allocation
bias. The cohort comprised 164 patients; 117 (71.3%) underwent liver resection first, whereas the
remaining 47 (28.7%) had preoperative chemotherapy. After a 1:1 ratio of propensity score
matching, 47 patients per group were evaluated. A positive resection margin was found in 13
patients in the surgery-first group (25.5%) versus 4 (8.5%) in the preoperative chemotherapy group
(P5 0.029). Postmatched logistic regression analysis showed that only preoperative chemotherapy
was significantly associated with the rate of positive resection margin (odds ratio 0.24, 95% con-
fidence interval 0.07–0.81; P 5 0.022). Median follow-up was 41 months (interquartile range 8–69).
Cox proportional hazard regression analysis revealed that only positive resection margin was a
significant negative prognostic factor (hazard ratio 2.2, 95% CI 1.18–4.11; P 5 0.014). Within the
preoperative chemotherapy group, median overall survival was 40 months in R0 patients and
10 months in R1 patients (P 5 0.016). Although preoperative chemotherapy in colorectal
liver metastasis patients may affect the rate of positive resection margin, its impact on survival
seems to be limited. In the present study, the most important prognostic factor was the resection
margin status.
R ESECTION MARGIN IS a well-established prognosticfactor in colorectal liver metastasis (CLM) pa-
tients. The presence of tumor cells in the resection
margin decreases the five-year survival by up to 20 per
cent. Conversely, disease-free margins (R0) are asso-
ciated with long-term survival, with five-year survival
rates >40 per cent.1, 2 Some authors have suggested
that the effect of an R1 resection on prognosis can be
cancelled out by modern preoperative chemother-
apy.1, 3–5 However, there are conflicting results on the
topic, with recent studies stating that preoperative
chemotherapy does not improve survival in margin-
positive patients.6, 7
In the present study, we compared the outcomes of
patients who received chemotherapy followed by re-
section with those of patients who had surgery first. In
particular, the analysis focused on the potential effect
of preoperative chemotherapy on resection margin
status and on the impact of the latter on survival,
exploiting propensity score matching.
Material and Methods
This retrospective cohort study was designed and
carried out in accordance with Strengthening the
Reporting of Cohort Studies in Surgery criteria.8 All
patients who had undergone liver resection with cu-
rative intent for CLMs at our center from July 1, 2001,
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to January 31, 2018, were included in the analysis. The
entire cohort was divided into two groups (pre-
operative chemotherapy and surgery first). The pri-
mary outcome measure was the rate of positive
resection margin. Secondary outcomes included over-
all survival (OS) and disease-free survival (DFS).
Resections resulting in macroscopic tumor residue or
re-resections were excluded from the analysis. Indi-
cations for preoperative chemotherapy/surgery first
were confirmed by a multidisciplinary team compris-
ing gastroenterologists, radiologists, oncologists, and
surgeons.
Definitions
A positive resection margin was defined as the
presence of cancer cells within 1 mm of the transection
margin. Major hepatectomy was defined as the re-
section of $4 liver segments.9 OS was defined as the
period from hepatectomy to the date of death/last
follow-up. DFS was defined as the period from liver
resection to the date of the first documented evidence
recurrence by imaging. Postoperative complications
were classified according to Dindo et al.10
Statistical Analysis
Continuous variables are presented as median and
interquartile range (IQR), whereas categorical vari-
ables are shown as percentages. Distribution differ-
ences were tested using the Mann-Whitney U test for
continuous variables and the Fisher’s exact test for
categorical variables. Propensity score matching
analysis was performed to minimize the potential se-
lection bias between the two groups. Variables in-
cluded in propensity score matching were age, gender,
American Society of Anaesthesiologists physical sta-
tus (ASA) score, number of lesions (>2 vs #2), and
type of primary (rectum vs colon) and synchronous
liver metastasis (yes vs no). A 1:1 nearest neighbor
matching algorithm without replacement was per-
formed using a specified caliper of 0.2 of the standard
deviation of the logit of the propensity score until all
possible matches had been formed, as reported
elsewhere.11
Kaplan-Meier survival analysis was used to deter-
mine survival variables and compared with log-rank
test. Cox proportional hazards regression was performed
TABLE 1. Types of Preoperative Chemotherapies Used
Therapy Number (%)
FOLFOX + bevacizumab 13 (27.7)
FOLFOX 13 (27.7)
FOLFIRI + bevacizumab 5 (10.6)
FOLFIRI + cetuximab 5 (10.6)
FOLFIRI 2 (4.2)
capecitabine, oxaliplatin 4 (8.5)
Other 5 (10.6)
TABLE 2. Patient Characteristics
Variables














(n 4 47) P
Effect
Size
Age $ 65 years,
n (%)
30 (63.8) 67 (57.3) 0.55 0.152 30 (63.8) 29 (61.7) 1.000 0.050
ASA > 2, n (%) 14 (29.8) 15 (12.8) 0.019 0.584 14 (29.8) 8 (17) 0.223 0.400
Rectal primary,
n (%)
12 (25.5) 26 (22.2) 0.803 0.101 12 (25.5) 12 (25.5) 1.000 0.000
Synchronous
metastasis, n (%)
30 (63.8) 45 (38.5) 0.005 0.572 30 (63.8) 30 (63.8) 1.000 0.000
K-Ras, n (%) 0.696* 0.156* 0.838* 0.029*
Wild type 22 (46.8) 29 (24.8) 22 (46.8) 14 (29.8)
Mutated 12 (25.5) 21 (17.9) 12 (25.5) 8 (17)
Not available 13 (27.6) 67 (57.3) 13 (27.6) 25 (53.2)
B-Raf, n (%) 0.121* 1.073* 0.305* 0.904*
Wild type 19 (40.4) 19 (16.2) 19 (40.4) 7 (14.9)
Mutated 7 (14.9) 1 (0.8) 7 (14.9) 0 (0)
Not available 21 (44.7) 97 (82.9) 21 (44.7) 40 (85.1)
No. lesions > 2,
n (%)
21 (44.7) 17 (6) 0.0001 0.859 21 (44.7) 17 (36.2) 0.065 0.195
Tumor sizey (cm),
median (IQR)
3 (1.7–4) 3 (2–4.5) 0.766 0.000 3 (1.7–4) 3 (2–4.2) 0.766 0.000
* Calculated on available data only.
y Diameter of the largest liver lesion.
Effect size values refer to comparison between preoperative chemotherapy and surgery first: values 0.2 indicate small differ-
ences, 0.5 indicate moderate differences, and 0.8 or more indicate considerable differences.
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to find the variables influencing OS and DFS. Follow-
up was calculated according to Schemper and
Smith.12 Logistic regression analysis was used to
determine the variables affecting the rate of positive
resection margin. Hazard ratios (HR), odds ratios
(OR), and 95% confidence intervals (95% CI) were
calculated when required. Analyses were performed
using MedCalc Statistical Software version 15.8
(MedCalc Software bvba, Ostend, Belgium; https://
www.medcalc.org; 2015).
Results
The cohort comprised 164 patients; 117 (71.3%)
underwent liver resection first, whereas the remaining
47 (28.7%) had preoperative chemotherapy. The type
of chemotherapy used is reported inT1 Table 1. The rate
of patients with ASA score > 2, synchronous metas-
tasis, and with >2 liver lesions differed significantly
between the two groups (T2 Table 2). After a 1:1 ratio of
propensity score matching, 47 patients per group were
included for analysis. No significant differences in base-
line characteristics were found between two groups in
the postmatch analysis (Table 2 andT3 3).
Postmatched Analysis
In the preoperative chemotherapy group, 33 cases
(70.2%) were judged technically resectable before
medical treatment. A positive resection margin was
found in 13 patients in the surgery-first group (25.5%)
compared with four (8.5%) in the preoperative che-
motherapy group (P 4 0.029). Logistic regression
analysis performed on 94 patients showed that only
preoperative chemotherapy was significantly associ-
ated with the rate of positive resection margin (OR
0.26, 95% CI 0.08–0.88); P 4 0.031) ( T4Table 4).
Survival Analysis
Median follow-up was 41 months (IQR 8–69). Me-
dian OS for the entire cohort (n 4 94) was 43 months
with a one-, three- and five-year survival of 78.2 per
cent, 61.2 per cent, and 31.4 per cent, respectively.
Median DFS was 17 months with a one-, three-, and
five-year survival of 57.2 per cent, 29.0 per cent, and
16.9 per cent, respectively. Median OS was 46 months
in the surgery-first group versus 39 months in the
preoperative chemotherapy group (P 4 0.929) ( F1Fig.
1). Cox proportional hazard regression showed that
only positive resection margin was significantly asso-
ciated with poor survival (HR 2.2, 95% CI 1.18–4.11;
P 4 0.014) ( T5Table 5) ( F2Fig. 2). In the preoperative
chemotherapy group, median OS was 40 months in R0
patients and 10 months in R1 patients (P 4 0.016)
( F3Fig. 3). Hepatic recurrence was recorded in 10 cases
in the preoperative chemotherapy group and in 12
cases in the surgery-first group (P 4 0.802). No sig-
nificant factors influencing DFS were found (Table 5).
Discussion
Preoperative chemotherapy was associated with a
higher rate of radical resection in our cohort. Two
studies reported no differences in R0 rates between
groups of patients submitted or not to preoperative
chemotherapy.3, 7 In 2014, these outcomes were con-
firmed in a meta-analysis of randomized trials13
TABLE 3. Matched Patients Operative and Postoperative Variables
Variables Preoperative Chemotherapy (n 4 47) Surgery First (n 4 47) P
Major liver resection, n (%) 7 (14.9) 9 (19.1) 0.784
Intraoperative transfusion, n (%) 3 (6.4) 3 (6.4) 1.000
Postoperative complications, n (%) 19 (40.4) 14 (29.8) 0.387
Clavien-Dindo > 2 2 (4.2) 5 (10.6) 0.432
Hospital stay (days), median (IQR) 9 (7-12) 9 (8-13) 0.229
TABLE 4. OR for R1 in the Matched Cohort
Variables OR (95% CI) P
ASA > 2 0.81 (0.29–2.19) 0.671
Age > 65 1.01 (0.96–1.07) 0.564
Gender—female 1.09 (0.34–3.52) 0.879
Rectal primary 0.91 (0.26–3.17) 0.891
No. of hepatic lesions > 2 1.16 (0.39–3.47) 0.782
Tumor diameter* 1.04 (0.88–1.21) 0.658
Synchronous metastases 0.99 (0.32–3.03) 0.999
Preoperative chemotherapy 0.26 (0.08–0.88) 0.031
* Analyzed as continuous variable.
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comparing outcomes of patients who underwent pre-
operative chemotherapy with those of patients receiv-
ing surgery alone: the pooled results of R0 resections
in the two groups were 86.5 per cent in the neoadjuvant
chemotherapy group and 84 per cent in the surgery-
alone group, although one of the included trials14 had
a significantly higher rate of R1 resections in the
surgery-alone group. A more recent meta-analysis by
Cui et al.15 found that neoadjuvant chemotherapy
associated with bevacizumab- and irinotecan-based
treatment plus targeted therapy significantly increased
R0 resection rates when compared with neoadjuvant
chemotherapy alone.
Our results seem to confirm Cui et al.’s finding: in
fact, 23 (48.9%) patients received preoperative folinic
acid, 5-fluorouracil, oxaliplatin/folinic acid, 5-fluor-
ouracil, and oxaliplatin (FOLFOX/FOLFIRI) plus
targeted therapy, whereas 18 (78.3%) underwent
treatment with bevacizumab. Preoperative chemo-
therapy did not affect OS in the cohort, and the sig-
nificant difference between the R0 and R1 groups was
also maintained in the subgroup receiving preoperative
chemotherapy. These findings are in line with those of
other authors.6, 7 Pandanaboyana et al.,7 analyzing
1255 patients, found that neoadjuvant chemotherapy in









FIG. 1. Kaplan-Meier survival curves comparing the two groups in the matched cohort.
TABLE 5. Cox Regression Analysis in the Matched Cohort
Variables
OS DFS
HR (95% CI) P HR (95% CI) P
ASA > 2 1.41 (0.68–2.93) 0.353 0.81 (0.45–1.45) 0.485
Age > 65 0.98 (0.95–2.95) 0.213 0.58 (0.34–0.96) 0.046
Gender—female 1.11 (0.57–2.14) 0.213 1.69 (0.95–3.00) 0.076
Rectal primary 0.69 (0.34–1.41) 0.312 0.67 (0.36–1.28) 0.229
No. of hepatic lesions > 2 1.31 (0.61–2.09) 0.694 1.14 (0.67–1.96) 0.612
Tumor diameter* 1.03 (0.9–1.18) 0.666 0.95 (0.84–1.08) 0.446
Synchronous metastases 1.27 (0.67–2.41) 0.465 0.96 (0.56–1.67) 0.895
Preoperative chemotherapy 0.97 (0.52–1.81) 0.929 1.1 (0.65–1.87) 0.724
Major resection 2.09 (0.86–5.06) 0.103 0.79 (0.31–1.99) 0.628
Transfusions 0.91 (0.34–2.37) 0.839 0.91 (0.33–2.53) 0.918
Postoperative complications 1.58 (0.85–2.95) 0.151 1.71 (0.99–2.95) 0.058
Positive resection margin (R1) 2.2 (1.18–4.11) 0.014 1.12 (0.55–2.31) 0.743
Adjuvant chemotherapy 0.81 (0.37–1.73) 0.586 1.53 (0.82–2.85) 0.183
* Analyzed as continuous variable.
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impact on recurrence or on the need for further liver
surgery. However, there several authors have reported
that preoperative chemotherapy guarantees the same
survival for both R0 patients and those who have
positive resection margins.1, 3–5 However, only four of
our patients who had preoperative chemotherapy were
R1, indicating the need to confirm our findings in
larger cohorts.
In the present study, the use of neoadjuvant chemo-
therapy did not have a significant impact on surgical
safety, as reported by others.16, 17 Even the patients who

















FIG. 2. Kaplan-Meier survival curves comparing R0 and R1 patients in the matched cohort.
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reported as a potential risk factor for increased post-
operative morbidity,18, 19 showed a similar rate of post-
operative complications to that of the general population.
Our study has a number of limitations because of the
retrospective nature of the analysis. First, information
on some parameters such as b-raf20 and inflammatory
prognostic scores,21, 22 which are acknowledged as
significant prognostic factors, could not be retrieved,
and this may have influenced the survival analysis.
Second, the chemotherapy drug schemes used were
heterogeneous in the preoperative chemotherapy group
and, thus, the specific effect of one treatment com-
pared with another could not be determined. Con-
versely, the main strength of this article lies in its use of
propensity score matching to reduce the selection bias
and increase our understanding of the real impact of
preoperative chemotherapy in two comparable groups.
In conclusion, although preoperative chemotherapy
in CLM patients may affect the rate of positive re-
section margin, its impact on survival seems limited. In
the present analysis, the most important prognostic
factor proved to be resection margin status.
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